Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.48 |
| ▸ | FLT3 | P36888 | 11/20 | 0.48 |
| ▸ | KIT | P10721 | 9/20 | 0.48 |
| ▸ | FLT1 | P17948 | 5/20 | 0.48 |
| ▸ | FLT4 | P35916 | 5/20 | 0.48 |
| ▸ | CSF1R | P07333 | 4/20 | 0.48 |
| ▸ | LCK | P06239 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.48 |
| ▸ | BLK | P51451 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | LYN | P07948 | 3/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | AXL | P30530 | 3/20 | 0.48 |
| ▸ | FRK | P42685 | 3/20 | 0.48 |
| ▸ | CSNK1G2 | P78368 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.48 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2816827 | 1.00 | KDR (0.48) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL15936499 | 0.89 | S1PR2 (0.41) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2819630 | 0.89 | KDR (0.57) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2816929 | 0.88 | HTR2A (0.51) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2818086 | 0.88 | KDR (0.50) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2818979 | 0.88 | KDR (0.48) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2818688 | 0.86 | KDR (0.45) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL12973338 | 0.86 | KDR (0.45) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2819532 | 0.84 | KDR (0.46) | KDRFLT3KITFLT1FLT4 | |
| SCHEMBL2819748 | 0.83 | KDR (0.53) | KDRFLT3KITFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7846928-B2 | Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-12-07 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058326-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, FLT1 | KDR 1/4885FLT3 39/4885KIT 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.